This finding showed that the hyperbilirubinemia observed in the patient was induced by the nilotinib administration and suggested that nilotinib therapy may inhibit UGT1A1 activity, including bilirubin glucuronidation. Here, UGT1A1 is linked to Hyperbilirubinemia.